Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …

Background Daratumumab, a monoclonal antibody targeting CD38, has been approved for
use with standard myeloma regimens. An evaluation of subcutaneous daratumumab …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Background In patients with newly diagnosed multiple myeloma, the effect of adding
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib …

The therapeutic landscape in multiple myeloma (MM) has changed dramatically over the last
2 decades. With the introduction of novel immunotherapies, patients with MM can expect …

PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …

Background Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-
RVd) in the GRIFFIN study improved the stringent complete response rate by the end of …

Background For patients with newly diagnosed multiple myeloma, reaching minimal residual
disease (MRD) negativity after treatment is associated with improved outcomes; however …

Background Lenalidomide is a cornerstone of maintenance therapy in patients with newly
diagnosed multiple myeloma after autologous stem-cell transplantation. We aimed to …

Due to evolving treatment standards for newly diagnosed multiple myeloma, many patients
will be triple-class exposed after initial relapses and have poor survival. Novel therapies and …